Journal
ONCOIMMUNOLOGY
Volume 8, Issue 11, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2019.1638212
Keywords
Antigen cross-presentation; DAMPs; immune checkpoint blockers; plasmacytoid dendritic cells; TLR signaling; tumor-infiltrating lymphocytes; clinical trial
Categories
Funding
- Research Foundation Flanders' (FWO) Excellence of Science (EOS) [30837538]
- KU Leuven via POR award funds [POR/16/040]
- FWO Postdoctoral Fellowship
- FWO fundamental research grants [G0584.12N, K202313N, GA01111N]
- KU Leuven [C24/18/064, C16/15/073]
- Kom Op Tegen Kanker (Stand up to Cancer)
- Flemish cancer society [2016/10728/2603]
- Olivia Fund [2017/LUF/00135]
- Ligue contre le Cancer (equipe labellisee)
- Agence National de la Recherche (ANR) - Projets blancs
- ANR
- ERA-Net for Research on Rare Diseases
- Association pour la recherche sur le cancer (ARC)
- Canceropole Ile-de-France
- Fondation pour la Recherche Medicale (FRM)
- Gustave Roussy Odyssea
- European Union
- Fondation Carrefour
- Highend Foreign Expert Program in China [GDW20171100085, GDW20181100051]
- Institut National du Cancer (INCa)
- Inserm (HTE)
- Institut Universitaire de France
- LeDucq Foundation
- LabEx Immuno-Oncology
- Seerave Foundation
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- US DoD
- Breast Cancer Research Program (BCRP) [BC180476P1]
- Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US)
- Phosplatin (New York)
- Sotio a.s. (Prague, Czech Republic)
- Chancelerie des universites de Paris (Legs Poix)
Ask authors/readers for more resources
Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available